STOCKS NEWS EUROPE-Antisoma rises after cancer drug update

Shares in cancer specialist Antisoma (ASM.L) rise 3.3 percent to 31 pence after the company releases fresh data for its leukaemia drug AS1411 in the run up to the American Society of Clinical Oncology annual meeting at the end of May.

"We believe AS1411 continues to show encouraging safety and efficacy in relapsed/refractory acute myeloid leukaemia," say analysts at Piper Jaffray in a note to clients.

The broker has a "buy" recommendation on the stock and a target price of 81 pence.

Reuters messaging rm://ben.deighton.thomsonreuters.com@reuters.net